Crispr Therapeutics AG vs VNET Group Inc — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while VNET Group Inc trades at $7.54 (market cap $2.14B). The key difference: Crispr Therapeutics AG is far larger — about 2.4× VNET Group Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | VNET | |
|---|---|---|
Market Cap | $5.23B | $2.14B |
Sector | Health | Technology |
52-Week High | $76.78 | $14.03 |
52-Week Low | $44.34 | $6.29 |
Enterprise Value | $3.65B | $5.29B |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →